Manually reviewing breast images for small abnormalities in a deluge of hundreds of mammographic images can mean long days for radiologists, which can lead to reader fatigue and increase the potential for missed cancers. False positives from older 2D computer-aided detection (CAD) technologies result in unnecessary biopsies, which are not only stressful for patients, they have been shown to cost the healthcare system more than billion per year.[i]

Artificial intelligence (AI) presents new opportunities to improve radi... Continue reading

IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reduced

NASHUA, N.H. – September 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, is providing additional comments following the Centers for Medicare & Medicaid Services’ (CMS) publication of a new Innovation Center model designed, according to... Continue reading

Research published in Radiology shows technology significantly outperforms existing breast cancer risk models, accelerating movement towards risk-adaptive screening

NASHUA, N.H. – September 15, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling data supporting ProFound AI™ Risk was published in the peer-reviewed journal, Radiology.[i] ProFound AI Risk is t... Continue reading

Leading experts in multiple disciplines to share best practices on leveraging AI in clinical settings

NASHUA, N.H. – September 9, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled “What is Real AI: Adopting Artificial Intelligence,” on September 15, 2020 at 7 pm ET/4 pm PT. Event registration is available via this lin... Continue reading

NASHUA, N.H., Aug. 27, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that management will present at the LD 500 Virtual Conference, hosted by LD Micro and taking place virtually September 1 – 4, 2020. Michael Klein, Chief Executive of iCAD, is scheduled to host a virtual presentation during the conference as follows and will participate in one-on-one meetings throughout the day.

LD 500 Virtual Investor Conference

Date:       &nbs... Continue reading

NASHUA, N.H., Aug. 10, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the Guggenheim MedTech Disruptors Summit, taking place virtually on August 10-11, 2020.

Presentation Details

Date: August 11, 2020

Time: 3:00pm Eastern Time

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader provid... Continue reading

Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe

Recent 50 System Agreement with SimonMed Imaging Highlights Significant Value of ProFound AI Solution

Expert Panel Reviews Compelling Clinical Data on Xoft® Brain IOR... Continue reading

NASHUA, N.H., July 28, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2020, after the market close, and host a conference call at 4:30 pm Eastern Time on Tuesday, August 4.

Tuesday, August 4th @ 4:30pmET

Domestic:

877-407-0784

Continue reading

NASHUA, N.H. – July 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Jeffrey Sirek was appointed as Senior Vice President and General Manager of Xoft.

“We are very pleased to add Mr. Sirek to our Company. He brings to the team a proven track record of high sales productivity, brand development, marketing success, and revenue growth,” said Stacey Steve... Continue reading

First and only commercially available clinical decision support tool provides accurate two-year breast cancer risk estimation personalized for each woman

iCAD unveils new technology and clinical research at major medical conference

NAS... Continue reading

According to the International Agency for Research on Cancer, in 2018 breast cancer accounted for 26.4 percent of all new cancer cases in European women.[i] Europe’s radiologist shortage, particularly in Scotland and the United Kingdom, where the shortage is dire, makes it hard to maintain medical standards.[ii] Without a sufficient number of radiologists for 1st and 2nd reads, there’s a risk that abnormalities may be missed.

The close scrutiny radiologists give to each image takes time and can be visually and mentally e... Continue reading

Leading-edge artificial intelligence (AI) software allows patients to receive “real time” essential breast screening amidst pandemic

NASHUA, N.H. and PHOENIX– July 13, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and SimonMed Imaging, one of the largest outpatient medical imaging providers and largest physician radiology practice... Continue reading

Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ lives

Overall survival benefit reached statistical significance in the IORT group with tumors less than or equal to 2.5 cm3 (p<0.05)

Researchers recently presented positive new clinical data supporting the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of gliob... Continue reading

Leading breast cancer specialists to share best practices on leveraging the latest in cancer therapies to enhance patient care and minimize virus exposure

iCAD hosted a free virtual roundtable event for clinicians, titled “The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy,” on June 4, 2020 at 7 pm ET/4 pm PT. To view the webinar on-demand, please visit this link: https://www.icadmed.com/educational-webinars.html.

 Continue reading

 Leading breast cancer specialists to share best practices on leveraging the latest in cancer therapies to enhance patient care and minimize virus exposure

NASHUA, N.H. – June 1, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled “The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy,” on June 4, 2020 at 7 pm ET/4 pm PT. Event registration is availa... Continue reading

Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ lives

Overall survival benefit reached statistical significance in the IORT group with tumors less than or equal to 2.5 cm3 (p<0.05)

NASHUA, N.H. – May 13, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced... Continue reading

Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives

Conference Call Today at 4:30 p.m. ET

NASHUA, N.H. – MAY 11, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the first quarter ended March 31, 2020

Recent Highlights:

NASHUA, N.H. , May 05, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2020, after the market close, and host a conference call at 4:30 pm Eastern Time on Monday, May 11.

Monday, May 11th @ 4:30pmET

Domestic:

888-394-8218

International:<... Continue reading

Wooster Community Hospital Adopts ProFound AI for Digital Breast Tomosynthesis to Optimize Breast Cancer Screening and Improve Workflow

iCAD’s educational webinar series recently featured Gabriele Pedicelli, MD, Radiologist at Wooster Community Hospital, who shared how ProFound AI™ not only improved workflow at his facility, it also resulted in a positive impact on his practice’s bottom line. Learn how this leading-edge AI tool empowered Dr. Pedicelli and his team to increase... Continue reading

NASHUA, N.H., April 23, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (Nasdaq: ICAD) today announced it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,562,500  shares of the Company’s common stock at .00 per share, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately .5 million before deducting estimated offering expenses. The Company intends to use the net proceeds for working capital and for other general corporate purposes, including for the conduct... Continue reading